Learning Objectives. Faculty. Why Treat Depression in Primary Care. A Real Case. Presenter Disclosure Information
|
|
- Thomas Stanley
- 5 years ago
- Views:
Transcription
1 2:15 3:30 pm Major Depressive Disorder: Improving Models for Care in the Primary Care Setting Presenter Disclosure Information The following relationships exist related to this presentation: Thomas Heinrich, MD, FAPM: No financial relationships to disclose. SPEAKER Thomas Heinrich, MD, FAPM Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Learning Objectives Faculty Thomas W. Heinrich, MD, FAPM Professor of Psychiatry and Family Medicine Vice Chair, Clinical Services Director, Division of Consultation-Liaison Psychiatry Medical Director, Process Improvement Inpatient Med/Surg Services, Froedtert Hospital Medical College of Wisconsin Milwaukee, WI Upon completion of these educational activities, participants should be able to: Recognize the importance of under-diagnosis and under-treatment of depression Improve routine screening for depression using a structured interview and standardized assessment tools including Measurement Based Initiatives (MBC) Assess optimal pharmacologic treatment options for patients with inadequate response to therapy Implement best practices in MDD treatment to attain the goal of complete remission, including support for medication adherence, adequate selection, dosing, and duration of drug therapy, follow-up, and reduction of residual symptoms A Real Case A 54 year old male with a history of HTN, HLD, and lung cancer presents for a follow-up visit after a hospitalization for nausea, vomiting, and dehydration He verbalizes problems sleeping and a poor appetite Records indicate that he has lost 6kg recently It is only as he is ready to leave that his wife states that she is worried about him being depressed Upon further question he endorses symptoms of depression, anhedonia, hopelessness, and decreased energy along with poor concentration Now what??? Why Treat Depression in Primary Care We are already doing it! 70% of patients with depression initially present with a physical symptom 41% of antidepressants are prescribed by PCPs We are likely going to be doing more of it! 55% of all psychiatrists are older than 55 years of age In 2015, there were about 17,000 US medical school graduates who matched into a residency Only about 4% (774) entered psychiatry residencies in 2015 Simon GE et al. N Engl J Med : Wang PS, et al. Arch Gen Psychiatry 62: , Last accessed on 1/2/ Last accessed 1/2/2016.
2 Depression General Adult Prevalence, Under-recognition, and Under-treatment Depression in Primary Care Under-recognition 50,371 patients were pooled across 41 studies 14 million Experience Depression The overall prevalence of depression (adjusted) was 19 5% (95% CI 15 7% to 23 7%) 7.2 million Treated 6.8 million Untreated Under-diagnosis Unable to access care Treatment refusal Stigma PCPs correctly identified depression 47 3% (95% CI 41 7% to 53 0%) However, diagnostic sensitivity varied greatly between individual studies, ranging from 6 6% to 78 8% Kessler RC, et al. JAMA. 2003;289(23): Mitchell AJ, et al. Lancet. 2009;22;374(9690): Depression General Adult Prevalence, Under-recognition, and Under-treatment Mental Health in Primary Care Under-treatment Poor Adherence 3.2 million Adequately Treated 7.2 million Treated 14 million Experience Depression 4 million Inadequately Treated 6.8 million Untreated Lack of efficacy Adverse events Poor adherence Safety concerns Percentile Antidepressant Adherence Rates Months % Continuing Therapy Risks for Poor Adherence Reluctance to initiate treatment Experience of unanticipated side effects No recollection of being told that the AD needed to be continued for at least 6 months Kessler RC, et al. JAMA. 2003;289(23): Olfson M, et al. Am J Psychiatry. 2006;163(1): Mitchell AJ. Lancet. 2006;367(9528): Impact of Depression Financial Cost Impact of Depression Preventable Costs Annual Costs (Thousands) (n=859) 1-2 (n=616) 3-5 (n=659) 6-16 (n=423) Chronic disease score No depression Mild depression Moderate to severe depression The risk of hospitalization for ACSC associated with depression Incidence rate ratio (95% CI) Any ACSC 1.53 (1.51 to 1.54) Chronic ACSC Angina 1.52 (1.49 to 1.56) COPD/asthma 1.66 (1.62 to 1.70) exacerbation CHF exacerbation 1.09 (1.06 to 1.12) Diabetes-related 1.86 (1.80 to 1.93) HTN 1.30 (1.26 to 1.34) p<0.001 Note: Adjusted for demographics, socioeconomic factors, predisposing comorbidity, and substance use disorders Unützer J, et al. JAMA. 1997;277(20): ACSC- ambulatory care-sensitive conditions Davydow DS et al. BMJ Open Dec 2;5(12):e
3 Impact of Depression Preventable Costs Impact of Depression Depression is Deadly: I The risk of rehospitalization within 30 days for ACSC associated with depression Incidence rate ratio (95% CI) Same ACSC 1.21 (1.18 to 1.24) Another ACSC 1.19 (1.15 to 1.23) p<0.001 Note: Adjusted for demographics, socioeconomic factors, predisposing comorbidity, and substance use disorders Odds Ratio Mortality Rate Over 7 Years Elderly Cohort 2,558 older adults from 4 primary care clinics. Mean age = 71. Odds ratios for mortality over 7-year follow-up. Adjusted for demographics and comorbid disorders. Arthritis HTN Cancer Depression Cardiac COPD Stroke DM RR Davydow DS et al. BMJ Open Dec 2;5(12):e Unützer J, et al. Am J Geriatr Psychiatry. 2002;10(5): Impact of Depression Depression is Deadly: III Diagnosis of Major Depression Differential Diagnosis Rate (per 100,000) U.S. Suicide Rates (All rates are per 100,000 population) Year Last accessed 1/2/2016. Total Male Female Suicide (2014) 43,773 deaths 10 th ranking cause of death in US 2 nd ranking cause of death for young in US 3.4 :1 male to female ratio 147 people are exposed to each suicide with 18 suffering serious adverse effects Nonfatal Outcomes (2014) 1,069,325 attempts in the US (estimate) 25 attempts for every death (estimate) :1 for young 4:1 for elderly 3:1 female to male ratio Medical Conditions (Partial List) Bipolar disorder Stroke Obstructive sleep apnea Anemia Organ failure (liver, kidney, lung, brain) Autoimmune disorder Thyroid abnormalities Adrenal insufficiency/cushings syndrome Electrolyte abnormalities Nutritional deficiencies HIV Cancer Schulz PE, et al. Continuum(Minneap Minn). 2015;21(3); Medications and Substances (Partial List) Steroids Isotretinoin Beta-interferon Antiepileptic medications Benzodiazepines Reserpine Alcohol Mercury Metoclopramide Methyldopa Bromocriptine Major Depression Treatment Options Pharmacologic - Antidepressants Psychotherapy Cognitive therapy Cognitive behavioral therapy (CBT) Interpersonal therapy Psychopharmacology Antidepressants Atypical antipsychotics Mood stabilizers Other potential therapies Electroconvulsive therapy (ECT) Transcranial magnetic stimulation (rtms) Vagal nerve stimulation (VNS) Deep brain stimulation (DBS) Exercise Bright light therapy Sleep deprivation Between 1999 and 2012 in the United States The percentage of adults treated with an antidepressant medication increased from 6.8% to 13.0% SSNRI: 0.4% 2.0% SSRIs: 4.3% 8.5% The percentage who underwent psychotherapy declined Top 4 selling classes of medications in 2009 in the U.S. 1. Antipsychotics ($14.6 billion) 2a. Acid reflux medications ($13.6 billion) 2b. Lipid regulators ($13.6 billion) 3. Antidepressants ($9.9 billion) Kantor ED, et al. JAMA. 2015;314(17): Olfson M, et al. Arch Gen Psychiatry. 2009;66(8): Last accessed 1/2/2016.
4 Pharmacologic - Antidepressants Antidepressants through the generations 1 st generation (MAOIs and TCAs) Increase extracellular monoamines, either through inhibition of catabolism or inhibition of reuptake 2 nd generation (SSRIs) Increase selectivity to reduce side effects No clear benefit in efficacy 3 nd generation (SNRIs, mirtazapine, bupropion, serotonin modulators) Back to multiplicity of action Multiple neurotransmitters Multiple mechanisms of action Multiple receptor sites No clear benefit in efficacy Pharmacokinetic Adverse Effects Inhibitors May lead to toxicity of a substrate May lead to loss of efficacy if a metabolite is the active agent Inducers May lead to a loss of efficacy if the substrate is the active agent Pharmacokinetic Adverse Effects Pharmacokinetic Adverse Effects CYP3A4 Inhibitors Fluoxetine Paroxetine Nefazodone CYP3A4 Substrates Diazepam Zolpidem Fentanyl Macrolide antibiotics Cyclosporine Ca Channel Blockers CYP2D6 Inhibitors Fluoxetine Paroxetine Sertraline Bupropion Duloxetine CYP2D6 Substrates TCAs Tramadol Oxyocodone Propranolol Tamoxifen Pharmacodynamic Adverse Effects Norepinephrine Serotonin Dopamine Histamine-1 antagonism -1 antagonism Muscarinic antagonism Anxiety Sympathomimetic effects Sexual side effects GI disturbances Serotonin syndrome Psychomotor activation Anxiety Nausea Sedation Weight gain Postural hypotension and dizziness Blurred vision Urinary retention and constipation Cognitive impairment Tricyclic antidepressants (TCAs) Names Tertiary: imipramine & amitriptyline Secondary: desipramine & nortriptyline Primary mechanism Block the presynaptic monoamine reuptake pump, thereby increasing the amount of monoamines in the synaptic cleft Therapeutic levels have been established for some Amitriptyline (combined amitriptyline plus metabolite nortriptyline) 80 to 200 ng/ml Nortriptyline 50 to 150 ng/ml Overdose risk 10 day supply can be fatal Nelson, JC. Tricyclic and tetracyclic drugs. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Washington, DC p.263.
5 Tricyclic Antidepressants Pharmacology m-ach receptors -1 receptors 5HT reuptake TCA Blockade of cardiac fast Na channels NE reuptake H1 receptors Selective Serotonin Reuptake Inhibitors (SSRIs) Primary mechanism Block the presynaptic serotonin reuptake pump, thereby increasing the amount of serotonin in the synaptic cleft Affect other neurotransmitters to different degrees All share certain properties Hepatically metabolized Relatively safe in overdose Generic Name Usual Daily Dose Generic Name Usual Daily Dose Citalopram 20-40mg/d Paroxetine 10-50mg/d Escitalopram 10-20mg/d Sertraline mg/d Fluoxetine 10-60mg/d Selective Serotonin Reuptake Inhibitors Pharmacology Antagonism of m-ach receptors Antagonis m of -1 receptors Blockade of cardiac fast Na channels 5-HT reuptake SRI Antagonis m of H1 receptors Inhibition of NE reuptake Inhibition of DA reuptake Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) Names Venlafaxine/Desvenlafaxine Serotonin (5HT) reuptake inhibitor at low dose Dual action (5HT/NE) reuptake inhibitor at higher doses Duloxetine Dual action (5HT/NE) reuptake inhibitor across dose range Levomilnacipran NE>5HT reuptake inhibition Some other potential indications Chronic MSK pain, neuropathic pain, and fibromyalgia Generic Name Usual Daily Dose Generic Name Usual Daily Dose Venlafaxine mg/d Duloxetine 30-60mg/d Desvenlafaxine mg/d Levomilnacipran mg/d Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Pharmacology m-ach receptors -1 receptors 5HT reuptake SNRI Blockade of cardiac fast Na channels NE reuptake H1 receptors Bupropion Mechanism Norepinephrine (NE) and dopamine (DA) reuptake inhibition Properties Minimal sedation Weight neutral SR formulation FDA-approved for nicotine dependence Contraindicated in patients with a history of seizures or eating disorders Generic Name Bupropion Usual Daily Dose mg/d
6 Bupropion Pharmacology m-ach receptors -1 receptors Blockade of cardiac fast Na channels 5HT reuptake Bupropion NE reuptake H1 receptors DA uptake Mirtazapine Mechanism Presynaptic alpha-2 NE blocker Postsynaptic 5HT2 and 5HT3 blocker Antihistaminic Minimally anticholinergic Side effects Sedation Weight gain Theoretically the antihypertensive effects of clonidine may be negated Serotonin Modulators Primary mechanism Block the presynaptic serotonin reuptake pump, thereby increasing the amount of serotonin in the synaptic cleft They are agonists, partial-agonists, or antagonists at various serotonin receptors Choice of antidepressant is largely based on the following factors Patient preference Nature of prior response to medication Patient and patient s family All share certain properties Hepatically metabolized Minimal weight gain Relatively safe in overdose Generic Name Vilazodone Vortioxetine Usual Daily Dose 10-40mg/d 10-20mg/d Safety, tolerability, and anticipated side effects Co-occurring psychiatric or general medical conditions properties of the medication Pharmacodynamic (neurotransmitters) Pharmacokinetic (half-life, metabolism, excretion) Cost Pharmacologic Acute Phase Evidence Treating Acute-Phase Major Depressive Disorder Outcome Strength of Evidence Findings Comparative efficacy Quality-of-life Onset of action Moderate Moderate Moderate Gartlehner G, et al. Ann Intern Med. 2011;155(11): Results from direct and indirect comparisons indicate that clinical response and remission rates are similar among secondgeneration antidepressants Consistent results indicate that the efficacy of second generation antidepressants regarding quality of life does not differ among drugs Consistent results suggest that mirtazapine has a statistically significantly faster onset of action than citalopram, fluoxetine, paroxetine, and sertraline Whether this difference favoring mirtazapine can be extrapolated to other second-generation antidepressants is unclear Most other trials do not indicate a faster onset of action of a particular second-generation antidepressant compared with another Antidepressant Medication Potential Adverse Effects In efficacy trials, an average of 63% of patients experienced at least one adverse event during treatment GI disturbances (diarrhea, nausea) Dizziness Dry mouth Fatigue Headache Overall, second-generation antidepressants caused similar adverse events The frequency of specific events differ among antidepressants Gartlehner G, et al. Ann Intern Med Dec 6;155(11): Sexual dysfunction Tremor Weight gain Sweating
7 Antidepressant Medication Potential Adverse Effects Weight Gain Antidepressant Medication Potential Adverse Effects Breakin the Bank Effect of AD on Weight Change (after >4m of Treatment) Medication Mean diff (Kg) 95% CI (Kg) P Paroxetine 2.73 (0.78 to 4.68) Mirtazapine 2.59 (-0.23 to 5.41) 0.07 Amitriptyline 2.24 (1.82 to 2.66) < Citalopram 1.69 (-0.97 to 4.34) NS Nortriptyline 1.24 (-0.51 to 2.59) NS Duloxetine 0.71 (-0.23 to 1.65) NS Escitalopram 0.65 (-0.97 to 4.34) NS Sertraline (-1.25 to 1.42) NS Fluoxetine (-1.04 to 0.43) NS Bupropion (-2.37 to -1.37) < day cost Antidepressant Mirtazapine 30mg/d Sertraline 100mg/d Citalopram 40mg/d Paroxetine 40mg/d Venlafaxine XL 150mg/d Bupropion XL 300mg/d Escitalopram 20mg/d Fluoxetine 40mg/d Desvenlafaxine 50mg/d Vilazodone 20mg/d Duloxetine 60mg/d Levomilnacipran 80mg/d Vortioxetine 10mg/d Available for $4 for a 30-day supply Serretti A, et al. J Clin Psychiatry 2010;71(10): LexiComp, Accessed 8/3/2015 Depression Treatment Goals Phases of Treatment The goals for depression treatment 1. Achieve remission 2. Restore optimal functioning 3. Prevent relapse 4. Minimize (or manage) treatment side effects Acute Phase 2-3 months Treatment goal is complete remission of symptoms Continuation Phase 4-9 Months Treatment goal is to prevent relapse of depression episode Maintenance Phase >1 year Treatment goal is to prevent a the occurrence of another episode of depression Davidson JR. J Clin Psychiatry. 2010;71(suppl E1) Kupfer DJ. J Clin Psychiatry. 1991;52 Suppl: Phases of Treatment STAR*D Trial Medication Algorithm Acute Phase 2-3 months Goal is remission Ensure treatment has been administered for a sufficient duration and dose 4 8 weeks are needed to determine responsiveness to a specific intervention Generally, no treatment should continue unmodified if there has been no symptomatic improvement after 1 month Considerations for treatment modification include Maximizing current treatment Switching medications Augmentation Citalopram Switch: bupropion SR, sertraline, or venlafaxine ER Augment: bupropion SR or buspirone Switch: mirtazapine or nortriptyline Augment: lithium or T3 Switch: Tranylcypromine or mirtazapine + venlafaxine ER Gelenberg AJ, et al. Practice guidelines for the treatment of patients with major depressive disorder. Third Edition. American Psychiatric Association Rush, A.J, et al. Am J Psychiatry. 2006;163:
8 STAR*D Trial Remission Rates STAR*D Trial Remission and Intolerance Rates Citalopram Switch: bupropion SR, sertraline, or venlafaxine ER Augment: bupropion SR or buspirone Switch: mirtazapine or nortriptyline Augment: lithium or T3 Overall Acute Remission Rates (QIDS-SR) 37% 31% 14% Citalopram Switch: bupropion SR, sertraline, or venlafaxine ER Augment: bupropion SR or buspirone Switch: mirtazapine or nortriptyline Augment: lithium or T3 Overall Acute Remission Rates (QIDS-SR) 37% 31% 14% Overall Intolerance Rates 16% 19% 26% 4 Switch: Tranylcypromine or mirtazapine + venlafaxine ER 13% 4 Switch: Tranylcypromine or mirtazapine + venlafaxine ER 13% 39% Rush, A.J, et al. Am J Psychiatry. 2006;163: Rush, A.J, et al. Am J Psychiatry. 2006;163: STAR*D Trial A Better More Real-World Trial? More than 82% of STAR*D participants overall would be ineligible for antidepressant registration trials 14% excluded for being older than 65 years of age 15% ineligible because their depression too mild 20% ruled out due to another medical condition(s) 21% of women would have been denied participation because they did not use birth control Phases of Treatment Continuation Phase 4-9 months For patients who achieve remission continue the medication for 4 9 months The same dose used during the acute phase to achieve remission should be utilized during the continuation phase, if tolerated Monitor for relapse, utilizing Patient Family Assessment tools (PHQ-9) Preskorn SH, et al. Journal Psychiatric Pract. 2015;21: Gelenberg AJ, et al. Practice guidelines for the treatment of patients with major depressive disorder. Third Edition. American Psychiatric Association Phases of Treatment Risk of Relapse and Recurrence Maintenance Phase 4-9 months Goal is to prevent future episodes of depression (i.e., recurrence) Determine individual risk factors for recurrence Requires a collaborative and open discussion with patient and others The same dose used during the acute and continuation phases should be utilized, if tolerated Monitor for recurrence (PHQ-9) Gelenberg AJ, et al. Practice guidelines for the treatment of patients with major depressive disorder. Third Edition. American Psychiatric Association Residual symptoms increase the risk of an early relapse or recurrence of major depressive The risk of recurrence after one episode of major depression 20% will recur within the first 6 months >50% will have at least one lifetime recurrence Most often within the first 2-3 years The risk of recurrence increases with each subsequent episode of major depression by 16% Lifetime maintenance should be seriously considered for patients with >3 episodes of major depression Mueller TI, et al. Am J Psychiatry 1999; 156 (7): Solomon DA, et al. Am J Psychiatry 2000; 157 (2):
9 Phases of Treatment American College of Physicians Discontinuation Phase Several weeks Goal is to prevent the discontinuation syndrome Gradual taper the antidepressant over at least several weeks Longer taper for medications with short half-lives (paroxetine and venlafaxine IR) Monitor the patient for recurrence of depression Gelenberg AJ, et al. Practice guidelines for the treatment of patients with major depressive disorder. Third Edition. American Psychiatric Association Qaseem A, et al. Ann Intern Med. 2008;149(10): Recommendation 1 The American College of Physicians recommends that when clinicians choose pharmacologic therapy to treat patients with acute major depression, they select second-generation antidepressants on the basis of adverse effect profiles, cost, and patient preferences Grade: strong recommendation; moderate quality evidence American College of Physicians American College of Physicians Recommendation 2 The American College of Physicians recommends that clinicians assess patient status, therapeutic response, and adverse effects of antidepressant therapy on a regular basis beginning within 1-2 weeks of initiation of therapy Grade: strong recommendation; moderate-quality evidence Recommendation 3 The American College of Physicians recommends that clinicians modify treatment if the patient does not have an adequate response to pharmacotherapy within 6-8 weeks of the initiation of therapy for major depressive disorder Grade: strong recommendation; moderate-quality evidence Qaseem A, et al. Ann Intern Med. 2008;149(10): Qaseem A, et al. Ann Intern Med. 2008;149(10): American College of Physicians Depression Treatment Recommendation 4 The American College of Physicians recommends that clinicians continue treatment for 4-9 months after a satisfactory response in patients with a first episode of major depressive disorder. For patients who have had 2 or more episodes of depression, an even longer duration of therapy may be beneficial Collaborative Care Coordinated care management which provides patient-orientated and guideline-based management to patients at the primary care level It is originally conducted on depressive patients Model has diversified to patients with other chronic illnesses Grade: strong recommendation; moderate-quality evidence Qaseem A, et al. Ann Intern Med. 2008;149(10):
10 What is Collaborative Care? Collaborative care (CC) is a systematic approach to the management of depression and/or other medical conditions disorders in medical settings It provides patients with specialty-level care within the context of their primary medical treatment through the use of a team-based approach Three core components 1. Systematic identification of patients with relevant psychiatric disorders via screening 2. Delivery of interventions by a team Patient Primary care provider Specialty physicians Nonphysician care managers 3. Treat-to-target approach based on careful monitoring of patient outcomes Rating scales Registry Screening Proposed New Recommendations USPSTF Depression in Adults: Screening 2015 (Proposed) Population Recommendation Grade General adult population, including pregnant and postpartum women The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. Last accessed 1/1/2016. B Screening - Instruments _Screening Instruments (PHQ-9) Depression Rating Scales Self-Report Test Beck Depression Inventory-II (BDI-II) Patient Health Questionaire-9 (PHQ-9) Patient Health Questionaire-2 (PHQ-2) Center for Epidemiologic Studies Depression Scale, Revised (CESD-R) Quick Inventory of Depressive Symptoms (QIDS-16) Geriatric Depression Scale (GDS) Edinburgh Postnatal Depression Scale (EPDS) Clinician-Administered Test Hamilton Depression Rating Scale (HAM-D) Montgomery-Asberg Depression Rating Scale (MADRS) PHQ-9 Scoring Key PHQ-9 Score Depression Severity 0-4 Minimal 5-9 Mild Moderate Moderately Severe Severe Kroenke K, et al. J Gen Intern Med. 2001;16(9): Screening Possible Flow The Real Case Part I Identify Need to Screen for Depression in Patient Population PHQ-2 PHQ-9 A 54 year old male with a history of HTN, HLD, and lung cancer presents for a follow-up visit after a hospitalization for nausea, vomiting, and dehydration He verbalizes problems sleeping and a poor appetite Records indicate that he has lost 6kg recently Physical examination is remarkable for notable muscle wasting and frailty Mental State Examination is normal, but he is obviously clinically depressed
11 The Real Case Part I (Continued) PHQ-9 indicates moderate depression (score of 13) You ask about depression He endorses multiple affective and neurovegatative symptoms of depression that have been present for over 2 months Detailed laboratory studies, including thyroid function tests, are all within normal limits You diagnose depression and initiate escitalopram You finish clinic early and make it home to dinner (on time) The Real Case Part II The patient meets with the care manager 1 week later, endorses multiple symptoms of depression, admits to not taking escitalopram She educates the patient and recommends continuation of escitalopram Fred s case is discussed at the weekly team meeting with the PCP, care manager, and psychiatrist since he is a new case Psychiatrist agrees with the initial choice of escitalopram After 8 weeks on a therapeutic dose of escitalopram serial PHQ-9 scores show minimal improvement (9-12), and he endorses intermittent nausea, poor appetite, and weight has dropped another 3 kg The Real Case Part II Case discussed with consulting psychiatrist due to failed medication trial Which antidepressant is most appropriate in this case? Mirtazapine Amitriptyline Nortriptyline Bupropion Continue with escitalopram The Real Case Part II The consulting psychiatrist recommended mirtazapine, due to the medications pharmacodynamic characteristics Serotonergic and noradrenergic properties may help treat the major depression 5-HT3 antagonism may help control the patient s complaint of nausea Histaminergic properties may help improve the patient s appetite and insomnia The Real Case Part III Conclusions Care manager is in contact with Fred every other week Repeat screening at 3-6 months done during medical follow-up indicates remission of depression (PHQ-9 scores of 2 and 3) Care manager discussed rationale for continued AD treatment with mirtazapine Sleeping well, appetite improved, and weight trending up Care manager contacts the patient via phone q3 months for next 12 months Monitor adherence, adverse effects, education, recurrence PCP, care manager, and psych in communication verbally and EMR Fred remains in remission from depression and is gaining weight Your high school senior just got a full scholarship to college Your CGCAHPS scores are in the 99% percentile Depression is common Untreated depression is associated with multiple adverse consequences Depression is poorly recognized in primary care, but tools exist to add in the diagnosis and management Depression is treatable and the goal of that treatment should be complete remission of depressive symptoms
Why Treat Depression in Primary Care. A Real Case. Depression General Adult Prevalence, Under-recognition, and Under-treatment
A Case Major Depressive Disorder: Improving Models for Care in the Primary Care Setting A 32 year old female without any past medical history presents with a month long history of sadness seeking help
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationAntidepressant Pharmacology An Overview
Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationAntidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationConsultant Pharmacist Approach to Major Depressive Disorder
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationConsultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More information3. Atypical antidepressants
3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More informationPart 2: Pain and Symptom Management Depression
Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationAffective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018
Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationElavil (amitriptyline)
Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationTreating Depression in Disadvantaged Women: What is the evidence?
Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationFocusing on Depression in the Community. Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy
Focusing on Depression in the Community Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy Disclosure and Conflict of Interest Dr. Gable declares no conflicts of interest, real
More informationTreating Chronic Illness in the PCMH Handout - Depression. A. Guidelines. 1. Control of Symptoms:
Treating Chronic Illness in the PCMH Handout - Depression A. Guidelines A quick note on diagnosis: Note: For a major depressive episode a person must have experienced at least five of the nine symptoms
More informationPamelor (nortriptyline)
Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor
More informationNortriptyline vs amitriptyline in elderly
Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationIndex. Bulimia, 13 Bupropion, 12, 51 Buspirone, 81
Index A α-adrenergic blockade, 55 Ablative neurosurgery, 83 Activity scheduling, 61 Acupuncture, 64, 69 71 Alcohol, 7, 13 Alprazolam, 50 Amfebutamone, 52 Amitriptyline, 34 Anhedonia, 13, 17, 18 Anterior
More informationEffective Treatment of Depression in Older African Americans: Overcoming Barriers
Effective Treatment of Depression in Older African Americans: Overcoming Barriers R U T H S H I M, M D, M P H A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F P S Y C H I A T R Y A N D B E
More informationAddressing Psychiatric Issues Prior to HCV Treatment. Glenn J. Treisman, MD, PhD The Johns Hopkins University School of Medicine Baltimore, Maryland
Addressing Psychiatric Issues Prior to HCV Treatment Glenn J. Treisman, MD, PhD The Johns Hopkins University School of Medicine Baltimore, Maryland Disclosure Information Dr Treisman has not relevant financial
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationMANAGEMENT OF VISCERAL PAIN
MANAGEMENT OF VISCERAL PAIN William D. Chey, MD, FACG Professor of Medicine University of Michigan 52 year old female with abdominal pain 5 year history of persistent right sided burning/sharp abdominal
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationDepressive Disorders A clinical overview. Dr. Scott Yarosh, Medical Director, Behavioral Health
Depressive Disorders A clinical overview Dr. Scott Yarosh, Medical Director, Behavioral Health Depressive Disorders What is depression? Complex series of conditions Physical component Emotional component
More informationStart Low, Go Slow but Treat to Target
Start Low, Go Slow but Treat to Target Pharmacotherapy for Depression, Anxiety and At-Risk Alcohol Use in Late Life September 29, 2014 Audio and Control Panel instruction On the phone? Raise your hand
More informationThe Context: Why is this so important to treat?
Depression for PG1s Ian A. Cook, M.D. UCLA Department of Psychiatry Laboratory of Brain, Behavior, and Pharmacology Semel Institute for Neuroscience & Human Behavior DepressionLA.com PsychiatryGuidelines.com
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 1 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationAnxiety Disorders- OCD. Peter Giacobbe MD FRCPC L. Ravindran MD FRCPC
Anxiety Disorders- OCD Peter Giacobbe MD FRCPC L. Ravindran MD FRCPC Anxiety Disorders - Epidemiology Anxiety disorders are the most common class of mental disorders Estimated lifetime prevalence rates
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Update: 2013 I have nothing to disclose Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California,
More informationPresenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy
Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado
More informationTREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD
TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationPsychiatric Consultant Role in Collaborative Care Sept 12, 2013
New York State Collaborative Care Initiative Psychiatric Consultant Role in Collaborative Care Sept 12, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationVolume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationDISEASES AND DISORDERS
DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
More informationPharmacy Technician Objectives. Pharmacist Objectives. Pre-Test Question 2. Pre-Test Question 1 9/27/2016. Disclosure and Conflict of Interest
Disclosure and Conflict of Interest Focusing on Depression in the Community Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy Dr. Gable declares no conflicts of interest, real
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2012 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More information